FTSE MIB
33.922,16 +40,66 (+0,12%) Dow Jones
37.986,40 +211,02 (+0,56%) Nasdaq
15.282,01 -319,49 (-2,05%) Nikkei 225
37.068,35 -1.011,35 (-2,66%) Petrolio
83,24 +0,51 (+0,62%) Bitcoin EUR
60.282,38 +713,37 (+1,20%)
Gilead Sciences, Inc. (GILD)
Dopo ore:
| Chiusura precedente | 66,16 |
| Aperto | 66,36 |
| Denaro | 66,74 x 500 |
| Lettera | 66,79 x 300 |
| Min-Max giorno | 66,16 - 66,82 |
| Intervallo di 52 settimane | 65,90 - 87,87 |
| Volume | |
| Media Volume | 7.421.214 |
| Capitalizzazione | 83,248B |
| Beta (5 anni mensile) | 0,20 |
| Rapporto PE (ttm) | 14,84 |
| EPS (ttm) | 4,50 |
| Prossima data utili | 25 apr 2024 |
| Rendimento e dividendo (futuro) | 3,08 (4,66%) |
| Data ex dividendo | 14 mar 2024 |
| Stima target 1A | 84,40 |
GlobeNewswireGlobal CAR T-cell Therapy Market Projected to Reach $83 Billion by 2032
PALM BEACH, Fla., Oct. 12, 2023 (GLOBE NEWSWIRE) -- FinancialNewsMedia.com News Commentary - Significant influences driving the CAR T-cell therapy market is a rising demand for model therapeutics for treatment of cancer, increase in prevalence of cancer and an escalating awareness of CAR T-cell therapy medicines. The CAR T-cell therapy market is currently going through a rapid expansion, owing to rapidly expanding clinical trial activities and recent commercialization of CAR-T cell therapy, whic
GlobeNewswireCenter for Disease Analysis Foundation Announces Receipt of an $8 Million Grant from Gilead Sciences to Relink Hepatitis B and C Patients to Care in the United States
LAFAYETTE, Colo., July 20, 2023 (GLOBE NEWSWIRE) -- The Center for Disease Analysis Foundation (CDA Foundation) announced today that it received an $8 million grant from Gilead Sciences (Nasdaq: GILD) as part of Gilead’s Relink grant program. CDA Foundation will disperse the grant to qualifying tax-exempt organizations to contact diagnosed but untreated patients with hepatitis C virus (HCV) or hepatitis B virus (HBV) infection to bring them back into care. Despite the availability of existing tr
